Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
47 Results for "
TLR8 AGONIST
" in MedChemExpress (MCE) Product Catalog:
Products (47)
47 Results for "TLR8 AGONIST" in MCE Product Catalog:
116
116 Publications Verification
Synonyms: R848; S28463
Target:
Research Areas:
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
14
14 Cited Publications
Synonyms: VTX-2337; VTX-378
Target:
Research Areas:
Motolimod (VTX-2337;VTX-378) is a selective Toll-like receptor 8 (TLR8) agonist, with an EC50 of approximately 100 nM.
3
3 Cited Publications
Research Areas:
CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages . CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production .
3
Target:
Research Areas:
CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively .
3
3 Cited Publications
Target:
Research Areas:
CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates TLR3, TLR8, and TLR9.
3
3 Cited Publications
Cat. No.: HY-128799A
CAS No.: 2990770-48-2
Research Areas:
CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages . CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production .
2
Target:
Research Areas:
Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection .
1
1 Cited Publications
Target:
Research Areas:
TLR7/8 agonist 1 dihydrochloride is a toll-like receptor TLR7/TLR8 dual-agonistic imidazoquinoline .
1
1 Cited Publications
Target:
Research Areas:
TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline.
1
1 Cited Publications
Synonyms: R848-d5; S28463-d5
Cat. No.: HY-20457
CAS No.: 1268163-15-0
Research Areas:
TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
Target:
Research Areas:
TLR8 agonist 5 is a potent TLR8 agonist with an EC50 value of 20 nM for HEK-Blue hTLR8. TLR8 agonist 5 activates the immune response .
Target:
Research Areas:
TLR7 agonist 1 is a selective TLR7 agonist with an LEC value of 90 nM. TLR7 agonist 1 activates downstream immune regulation and shows no activity against TLR8. TLR7 agonist 1 induces endogenous IFN-α production in mice .
Synonyms: T785 hydrochloride
Target:
Research Areas:
AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist. AXC-715 can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
Cat. No.: HY-13740G
CAS No.: 144875-48-9
Synonyms: R848 (GMP); S28463 (GMP)
Cat. No.: HY-164485
CAS No.: 2549050-07-7
Target:
Research Areas:
INI-4001 is a TLR7/8 agonist and vaccine adjuvant. INI-4001 regulates innate and adaptive immune responses by activating murine TLR7 and human TLR7/TLR8. INI-4001 enhances IgG and neutralizing antibody responses against Powassan virus (POWV), reduces viral loads in the brain, liver and spleen, provides complete protection against lethal POWV challenge, and skews immune responses toward a Th1 phenotype. When INI-4001 is used in combination with Al (OH)3 and SARS-CoV-2 RBD antigen, it efficiently adsorbs to Al (OH)3, promotes Th1 immunity and enhances SARS-CoV-2 neutralizing antibody responses. INI-4001 is applicable to research related to Powassan virus infection and COVID-19 .
Cat. No.: HY-145885
CAS No.: 2115702-83-3
Research Areas:
TLR7/8 agonist 6 is a TLR7/8 agonist with EC50s of 0.18 μM and 5.34 μM in TLR7 or TLR8 HEK-SEAP reporter cells, respectively. TLR7/8 agonist 6 potently stimulates production of TNFα, IFNγ, and IL-1β. TLR7/8 agonist 6 can be used for research on cancer and infectious diseases .
Target:
Research Areas:
TLR7/8 agonist 3 (Compound II) is a potent TLR7 and TLR8 agonist, extracted from patent WO2016057618 (compound of formula (II)) .
Target:
Research Areas:
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of TLR7/8 with IC50s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases .
Cat. No.: HY-141454
CAS No.: 2412937-64-3
Target:
Research Areas:
TLR8 agonist 2 is a potent and selective TLR8 agonist with an EC50 of 3 nM for human TLR8. TLR8 agonist 2 shows less active against human TLR7 (EC50 of 33.33 μM) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
